Afficher la notice abrégée

The incidence of post-transplant malignancies in kidney transplant recipients treated with Rituximab

dc.rights.licenseopenen_US
dc.contributor.authorBACHELET, T.
hal.structure.identifierImmunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]
dc.contributor.authorVISENTIN, Jonathan
dc.contributor.authorDAVIS, P.
dc.contributor.authorTATON, B.
dc.contributor.authorGUIDICELLI, G.
hal.structure.identifierImmunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]
dc.contributor.authorKAMINSKI, Hannah
hal.structure.identifierImmunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]
dc.contributor.authorMERVILLE, Pierre
hal.structure.identifierImmunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]
dc.contributor.authorCOUZI, Lionel
dc.date.accessioned2022-11-15T09:06:37Z
dc.date.available2022-11-15T09:06:37Z
dc.date.issued2021-02
dc.identifier.issn1399-0012en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/170260
dc.description.abstractEnBackground: Rituximab has been proposed as induction therapy in kidney transplant recipients (KTRs) with preformed donor-specific antibodies (DSA) or a positive flow cross-match. We here evaluated whether adding rituximab was associated with a higher incidence of post-transplant malignancies (PTM) due to greater immunosuppression. Patients and Methods: Forty-eight HLA-sensitized KTRs received induction therapy with anti-thymocyte globulin (ATG) and rituximab because of preformed DSA or a positive flow cross-match (RTX group). They were compared with a control group of 154 patients receiving ATG alone. Results: Thirty-nine of 202 (19.3%) patients developed PTM; the rate was similar in the RTX and no-RTX groups (14.6% vs. 20.8%, respectively, P=.3). The distributions of the types of cancer were similar between the two groups, with the majority being non-melanoma skin cancer (NMSC, n=24). The risk factors for PTM were male gender, age, history of cancer, and azathioprine. Conclusion: Our data do not indicate a higher rate of post-transplantation de novo malignancies after kidney transplantation in high-immunological risk patients who received induction therapy based on ATG and rituximab.
dc.language.isoENen_US
dc.subject.enAlloantibodies
dc.subject.enB-cell therapy
dc.subject.enMalignancy
dc.subject.enRituximab
dc.title.enThe incidence of post-transplant malignancies in kidney transplant recipients treated with Rituximab
dc.typeArticle de revueen_US
dc.identifier.doi10.1111/ctr.14171en_US
dc.subject.halSciences du Vivant [q-bio]/Immunologieen_US
dc.identifier.pubmed33247459en_US
bordeaux.journalClinical Transplantationen_US
bordeaux.pagee14171en_US
bordeaux.volume35en_US
bordeaux.hal.laboratoriesImmunoConcEpT - UMR 5164en_US
bordeaux.issue2en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionCNRSen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03852645
hal.version1
hal.date.transferred2022-11-15T09:06:41Z
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Clinical%20Transplantation&rft.date=2021-02&rft.volume=35&rft.issue=2&rft.spage=e14171&rft.epage=e14171&rft.eissn=1399-0012&rft.issn=1399-0012&rft.au=BACHELET,%20T.&VISENTIN,%20Jonathan&DAVIS,%20P.&TATON,%20B.&GUIDICELLI,%20G.&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée